Osteogenic capacity of mesenchymal stem cells from patients with osteoporotic hip fractures in vivo. (4th May 2022)

• Record Type: Journal Article
• Authors: López-Delgado, Laura; del Real, Alvaro; Sañudo, Carolina; Garcia-Ibarbia, Carmen; Laguna, Esther; Menendez, Guillermo; Garcia-Montesinos, Belen; Santurtun, Ana; Merino, Jesus; Pérez-Núñez, María I; Riancho, Jose A.
• Is Part Of: Connective tissue research. Volume 63:Number 3(2022)
• Page Start: 243
• Page End: 255
• Publication Date: 2022-05-04
• Subjects: Bone formation -- osteoblasts -- mesenchymal stem cells -- cell senescence -- bone nodules -- in vivo; Connective tissues -- Periodicals; 616.770072
• DOI: 10.1080/03008207.2021.1894140
• Languages: English
• ISSNs: 0300-8207

Abstract

ABSTRACT: Purpose: Human mesenchymal stem cells (MSCs) have the ability to differentiate into bone-forming osteoblasts. The aim of this study was to elucidate if MSCs from patients with OP show a senescent phenotype and explore their bone-forming ability in vivo. Materials and methods: MSCs from patients with OP and controls with osteoarthritis (OA) were implanted into the subcutaneous tissue of immunodeficient mice for histological analysis and expression of human genes by RT-PCR. The expression of senescence-associated phenotype (SASP) genes, as well as p16, p21, and galactosidase, was studied in cultures of MSCs. Results: In vivo bone formation was evaluated in 103 implants (47 OP, 56 OA). New bone was observed in 45% of the implants with OP cells and 46% of those with OA cells (p = 0.99). The expression of several bone-related genes (collagen, osteocalcin, alkaline phosphatase, sialoprotein) was also similar in both groups. There were no differences between groups in SASP gene expression, p16, and p21 expression, or in senescence-associated galactosidase activity. Conclusion: Senescence markers and the osteogenic capacity in vivo of MSCs from patients with OP are not inferior to that of cells from controls of similar age with OA. This supports the interest of future studies to evaluate the potential use of autologous MSCs from OP patients in bone regeneration procedures.